Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1148P - Identification and validation of RET fusions in lung adenocarcinoma through DNA and RNA sequencing


16 Sep 2021


ePoster Display


Tumour Site

Non-Small Cell Lung Cancer


Yuchen Han


Annals of Oncology (2021) 32 (suppl_5): S921-S930. 10.1016/annonc/annonc707


Y. Han, C. Xiang, L. Guo, R. Zhao, A. Yu

Author affiliations

  • Department Of Pathology, Shanghai Chest Hospital, Shanghai Jiao Tong University, 200030 - Shanghai/CN

Abstract 1148P


RET fusion has emerged as a targetable oncogenic driver in non-small cell lung cancer. The optimal methods to identify actionable RET fusions during clinical practice remain to be evaluated. Herein, we performed a comparative analysis on RET fusions using targeted next-generation sequencing at DNA (DNA-seq) and RNA (RNA-seq) levels.


A total of 53 lung adenocarcinoma patients harboring non-canonical RET fusions identified by DNA-seq were selected to receive RNA-seq of their remaining tumor samples using a 115-cancer gene panel (OncoRNA). Of them, 43 passed quality control of RNA-seq. The breakpoints and partners of RET-fusion identified by DNA- and RNA-Seq were described and compared.


Of the 43 patients, DNA-seq identified 25 patients with concurrent 5’ RET fusions and 3’ canonical RET fusions (KIF5B-RET (K15:R12) or CCDC6-RET (C1:R12), subgroup A), 2 patients with 5’ RET fusions alone (subgroup B), 8 patients with frameshift or out-of-frame fusions (subgroup C) and 8 patients with 3’ non-canonical RET fusions alone (subgroup D). In total, 40 of 43 patients (93%) were positive for RET-fusions at RNA level. In subgroup A, RNA-seq detected all canonical RET-fusions with identical breakpoints to DNA-seq, while no transcripts of the 5’ RET fusions were detected. Patients in subgroups B and C did not have in-frame actionable fusions detected by DNA-seq. However, in subgroup B, RNA-seq identified 1 KIF5B-RET transcript with rare breakpoint (K24:R10). In subgroup C, only 1 patient was negative while 7 patients were positive at RNA level including 6 with canonical RET fusions of which the RET breakpoints were identical to DNA-seq. The discordance might be explained by complex DNA structural rearrangements and RNA splicing. In subgroup D, RNA-seq identified 7 of 8 patients with RET fusions concordant with DNA-seq, and 1 patient was negative. Most RET fusions in this subgroup involved rare partners including KIAA1468, LMNA, TRIM33, EDC4, ANKRD26, and AKAP13.


DNA-seq and RNA-seq showed high consistency in detecting RET fusions. RNA-seq could be valuable in determining the actionability of 5’ or frameshift/out-of-frame DNA fusions.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.